Results 61 to 70 of about 409,524 (305)

Monitoring of biomarkers in heart failure. [PDF]

open access: yes, 2019
The role of biomarkers is increasingly recognized in heart failure (HF) management, for diagnosis, prognostication, and screening of high-risk patients.
Agewall   +43 more
core   +1 more source

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman   +7 more
wiley   +1 more source

Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso

open access: yesBMC Bioinformatics, 2023
In clinical trials, identification of prognostic and predictive biomarkers has became essential to precision medicine. Prognostic biomarkers can be useful for the prevention of the occurrence of the disease, and predictive biomarkers can be used to ...
Wencan Zhu   +2 more
doaj   +1 more source

Therapeutic Apheresis for Intravenous Methylprednisolone‐Refractory Neuromyelitis Optica Spectrum Disorder: Clinical and Radiological Outcomes in a Single‐Center Case Series

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system. High‐dose intravenous methylprednisolone (IVMP) is the standard first‐line therapy for acute attacks, although some patients remain refractory.
Wataru Horiguchi   +5 more
wiley   +1 more source

Prognostic Biomarkers in Sepsis

open access: yesEurasian Journal of Critical Care, 2023
We read with great interest the article titled “Evaluation and Diagnostic Effectiveness of Hemogram, Biochemistry and Inflammatory Markers (Immature Granulocyte, Procalcitonin, CRP, NLR, PLR) in Patients with Sepsis” prepared by Gedik and Çiftçioğlu and published in the second issue of your journal in 2023.
openaire   +2 more sources

Organoids in pediatric cancer research

open access: yesFEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. [PDF]

open access: yes, 2018
The introduction of serum Prostate Specific Antigen (PSA) testing nearly 30 years ago has been associated with a significant shift towards localized disease and decreased deaths due to prostate cancer.
Auman, Heidi   +16 more
core   +2 more sources

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

open access: yesFEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

A biomarker guided approach in heart failure [PDF]

open access: yes, 2014
Heart failure is one of the commonest diagnoses presenting to physicians in the community or hospital care. Symptoms are often subjective, with clinicians having to rely on clinical assessment and radiological imaging to manage these patients.
Abela, Mark
core  

How to mend a broken heart? [PDF]

open access: yes, 2018
No abstract ...
Berry, Colin   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy